Statement of Ownership (sc 13g)
February 12 2014 - 6:13AM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
Under the Securities Exchange Act of
1934
INFORMATION TO BE INCLUDED IN STATEMENTS
PURSUANT TO RULES
13d-1(b), (c) AND (d) AND AMENDMENTS
THERETO FILED PURSUANT TO RULE 13d-2(b)
(Amendment No. )*
ARNO
THERAPEUTICS, INC.
(Name of Issuer)
COMMON
STOCK
(Title of Class of Securities)
042564203
(CUSIP Number)
12/31/2013
(Date of Event Which Requires Filing of
this Statement)
Check the appropriate
box to designate the rule pursuant to which this Schedule is filed.
*The remainder
of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover
page.
The information
required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes).
Page 1 of 5 Pages
CUSIP No. 042564203
|
SCHEDULE 13G
|
Page 2 of 5 Pages
|
1
|
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
(ENTITIES ONLY)
FROST
GAMMA INVESTMENTS TRUST
46-0464745
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
|
(a)
¨
(b)
¨
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
FLORIDA
|
NUMBER OF
|
5
|
SOLE VOTING POWER
|
2,062,500 (1)
|
SHARES
BENEFICIALLY
|
6
|
SHARED VOTING POWER
|
0
|
OWNED BY
EACH
|
7
|
SOLE DISPOSITIVE POWER
|
2,062,500 (1)
|
REPORTING
PERSON WITH
|
8
|
SHARED DISPOSITIVE POWER
|
0
|
9
|
2,062,500 (1)
|
10
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES
CERTAIN SHRES*
¨
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT
IN ROW (9)
9.48%
|
12
|
TYPE OF REPORTING PERSON*
oo
|
(1) Includes 687,500 shares of common stock
and warrants to purchase 1,375,000 shares of common stock.
CUSIP No. 042564203
|
SCHEDULE 13G
|
Page 3 of 5 Pages
|
Item 1(a).
|
Name of Issuer. Arno Therapeutics, Inc.
|
|
|
Item 1(b).
|
Address of Issuer’s Principal Executive Offices.
|
|
4 Campus Drive, 2
nd
Floor
|
|
Parsippany, NJ 07054
|
|
|
Item 2(a).
|
Name of Person Filing.
|
|
|
|
Frost Gamma Investments Trust
|
|
|
Item 2(b).
|
Address of Principal Business Office or, if None, Residence.
|
|
4400 Biscayne Boulevard
|
|
Miami, FL 33137
|
|
|
Item 2(c).
|
Citizenship.
|
|
|
|
The Trust is established in Florida
|
|
|
Item 2(d).
|
Title of Class of Securities.
|
|
|
|
Common Stock
|
|
|
Item 2(e).
|
CUSIP Number.
|
|
|
|
042564203
|
|
|
Item 3.
|
If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), identify the status of the person filing.
|
|
|
|
Not Applicable
|
|
|
Item 4.
|
Ownership.
|
|
(a) Amount beneficially owned:
|
2,062,500 (1)
|
|
|
|
|
(b) Percent of class:
|
9.48%
(2)
|
(c) Number of shares
as to which such person has:
|
(i)
|
Sole power to vote or direct the vote:
|
2,062,500 (1)
|
|
(ii)
|
Shared power to vote or direct the vote:
|
0
|
|
|
|
|
|
(iii)
|
Sole power to dispose or direct the disposition of:
|
2,062,500 (1)
|
|
(iv)
|
Shared power to dispose or direct the disposition of:
|
0
|
|
(1)
|
Includes 687,500 shares of common stock and warrants to purchase 1,375,000 shares of common stock.
|
|
(2)
|
The percentage is calculated based upon the
20,370,331
shares of Common Stock issued and
outstanding as of
November 12, 2013
per the
10-Q f
iled on
November 14, 2013.
|
CUSIP No. 042564203
|
SCHEDULE 13G
|
Page 4 of 5 Pages
|
Item 5.
|
Ownership of Five Percent or Less of a Class.
|
|
|
|
If this Statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.
¨
|
|
|
Item 6.
|
Ownership of More than Five Percent on Behalf of Another Person.
|
|
|
|
Not Applicable
|
|
|
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
|
|
|
|
Not Applicable
|
|
|
Item 8.
|
Identification and Classification of Members of the Group.
|
|
|
|
Not Applicable
|
|
|
Item 9.
|
Notice of Dissolution of Group.
|
|
|
|
Not Applicable
|
|
|
Item 10.
|
Certification.
|
|
|
|
Not Applicable
|
CUSIP No. 042564203
|
SCHEDULE 13G
|
Page 5 of 5 Pages
|
SIGNATURES
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
February 12, 2014
|
Frost Gamma Investments Trust
|
|
|
|
/s/ Phillip Frost, MD
|
|
By: Phillip Frost, MD
|
|
|
|
Title: Trustee
|
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From May 2024 to Jun 2024
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jun 2023 to Jun 2024